PARG and melanoma: Recently PARG inhibitors has been suggested for alternative specific treatment for BRCA2-deficient and other HR-deficient tumors as single therapy [43], and the inhibitor GPI16552 has also been used previously in combination with the methylating agent temozolomide to reduce tumor cell growth, metastasis and prolong life in mice injected subcutaneously or intracranially with B16 melanoma cells [46].